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Abstract
Frankfurt, Paige A. Ph.D. The University of Memphis. August, 2016 A Home-Based
Biofeedback Intervention in A Hypertensive African American Sample: A Pilot Study. Frank
Andrasik, Ph.D.

Approximately 70-80 million people in the US have hypertension. Left untreated, it can lead to
heart disease and stroke, the 1st and 2nd leading causes of death in the US, respectively. African
Americans (AA) are at particular risk for developing hypertension and, when present, they
experience increased morbidity and mortality, in comparison to other races, as well as elevated
risk of psychological distress. Further, when treated with the prevailing approaches, AAs
experience more adverse side effects and often face a greater number of challenges with
adherence. Despite some successful efforts at reducing high BP in general hypertensive
populations, AAs continue to struggle greatly with this condition. The primary purpose of this
research was to test the utility of the RESPeRATE, a home-based biofeedback device approved
for treatment of hypertension, in augmenting care of AAs currently receiving medical treatment
but who were not responding at an optimal level. A secondary aim of this study was to examine
the impact of treatment on psychological effects of individuals with hypertension. This was
accomplished in a small-scale pilot investigation comparing those continuing on their current
treatment, or Treatment as Usual (TAU), to those continuing TAU + the addition of the
RESPeRATE device. Multiple measures were collected at baseline, immediate post-treatment,
and follow ups at 3 and 6 months. In addition to ongoing assessments of BP, the Perceived Stress
Scale (PSS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and the Quality
of Life Questionnaire (QoL) were collected for 2 purposes: as potential predictors of treatment
response and to track collateral improvements over time. Gender, specifically being female,
significantly predicted reductions in systolic blood pressure at the end of the intervention
v

(β=8.34, SE = .66, t (28) = 12.63, p <.001). Similarly, age significantly predicted successful
reductions in systolic BP at the end of the intervention β=-.26, SE= .04, t(28)=.6.52, p< .001.
Keywords: African Americans, hypertension, high blood pressure, home-based,
biofeedback
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A Home A Home-Based Biofeedback Intervention in A Hypertensive African American Sample:
A Pilot Study
Introduction
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure defines hypertension as an elevated systolic blood pressure (BP) of >150 mmHg
and diastolic BP of > 90 mmHg, in adults 60 years and older, or 140mmHg and diastolic BP of
> 90 mmHg, in adults younger than 60 (James et al., 2014). Left untreated, it can lead to heart
disease and stroke, the 1st and 2nd leading causes of death in the US, respectively (World Health
Organization (WHO), 2011). Approximately 70-80 million people in the US have hypertension
(American Heart Association, 2012; Center for Disease Control, 2011). High BP imposes a huge
weight on society as a whole, varying as a function of gender and race (among other aspects),
with this condition worsening with age due to the stiffening of the arterial walls. By age 64, more
women are affected than men. The economic burden of hypertension, when left untreated, is
large. Recent studies found that the overall economic burden of high BP is approximately $156
billion dollars per year [in healthcare services and costs, missed days of work, and general
medications (Department of Health and Human Services (DHHS), 2012)], and, by 2030, it is
projected to increase to nearly $200 billion dollars per year (Heidenreich et al., 2011).
Multiple causes of hypertension have been identified including biology, genetics, drugs and
diseases, and lifestyle choices. Therefore, interventions have focused efforts for reducing BP on
these areas. Studies typically have focused on reducing BP through lifestyle/diet modifications,
administering antihypertensive drug therapy (ADT), providing education and stress-reduction
approaches using biofeedback, meditation, and paced breathing techniques (Appel et al., 1997;
Barnes, Treiber, & Johnson, 1997; DeSimone & Crowe, 2009; Lochner, Rugge, & Judkins,
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2005; Rankins, Sampson, Brown, & Jenkins-Salley, 2005; Svetsky et al., 1999; Tilburt, Dy,
Weeks, Klag, & Young, 2008). Despite some successful efforts at reducing high BP in general
hypertensive populations, AAs continue to struggle with BP (Rankins et al., 2005; Svetkey et al.,
1999). In non-AA samples, significant reductions in BP from lifestyle/diet modifications and
ADTs have been found. However, research has shown that AAs experience more adverse side
effects and challenges with adherence to these treatments, an alarming situation since these
approaches are the gold standard at present for effective high BP intervention (Fongwa et al.,
2008; Lloyd-Jones et al., 2010; Mellen, Gao, Vitolins, & Goff, 2008; Mozaffarian et al., 2015).
In addition to the above-mentioned problems, AAs have been found to exhibit different
physiological reactions in response to psychosocial and emotional stress (anger, depression,
anxiety), as compared to their Caucasian, Hispanic, or Asian counterparts (Artinian, Washington,
Flack, Hockman, & Kai-Lin, 2006; Gonzales & Thomas, 2011; Horowitz, Tuzzio, Rojas,
Monteith, & Sisk, 2004; Merritt, Bennet, Williams, Sollers, & Thayer, 2004; Taylor,
Washington, Artinian, & Lichtenberg, 2008). Anderson and Nurckhardt (1999) posit that AAs
experience stress more chronically than European Americans, suggesting one possible reason for
the higher rates of hypertension in AAs. When humans experience hyperactivity of the
Sympathetic Nervous System (SNS) (i.e., increases in heart rate, respiratory rate, blood pressure
and metabolic rate) in the face of acute and chronic stressors, an imbalance in the autonomic
nervous system occurs. Over time, this imbalance can lead to deterioration of renal functioning,
increased production of sodium-retaining hormones, stiffening of and reduced strength of the
arterial walls, and, ultimately, increased blood pressure and cardiovascular disease (Oparil,
Zaman, & Calhoun, 2003). Research has shown that the majority of AAs are genetically
predisposed to increased sodium retention, which is associated with hypertension. When
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considering the abovementioned stress response that AAs experience, it stands to reason that
prolonged physiological reactions to stress in AAs (i.e., discrimination) helps to explain the
higher rates of hypertension (Dusek & Benson, 2009; 2000; Knox, Hausdorff, & Markowitz,
2002; Merritt et al., 2004).
The disparate rates of hypertension (HTN) among African Americans arise in part due to
several psychosocial stressors that have been identified as barriers to medical treatment and
overall life stressors (Kaplan & Nunes, 2003; Paradies, 2004, 2006), including lower
socioeconomic status (SES), lack of access to health care services and accurate health
information, cultural beliefs and attitudes, and limited social support (Borzecki, Oliveria, &
Berlowitz, 2005; Centers for Disease Control and Prevention, 2005). One such cultural belief/
attitude is embodied in the John Henryism (JH) theory, which has been applied to African
Americans and suggests that prolonged exposure to stressors, including social discrimination,
results in compromised physiological effects (i.e.,hypertension). Specifically, it suggests that
high effort, combined with sustained active coping, but with limited socioeconomic resources to
draw upon (lower education, income, etc.) sets the occasion for blood pressure to increase. This
view has found support in several studies (Fernander, Duran, Saab, & Schneiderman, 2004;
James, Keenan, Strogatz, Browning, & Garrett, 1992; Merritt et al., 2004). Furthermore, research
suggests that use of an active coping when few socioeconomic resources are available may not
only increase the risk of HTN but also cardiovascular disease. These increased risks can occur as
a result of heightened sympathetic nervous system activity, cardiovascular reactivity, and
delayed resilience to stress (Merritt et al., 2004).
One possible theory whose application could help reduce cardiovascular reactivity and
resilience to stress focuses on the relaxation response (RR) in an attempt to slow down the SNS.
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As discussed above, the role of SNS activation as a contributing factor to HTN has led
investigators to explore alternative ways of counteracting this factor. Different forms of
relaxation, including regulated breathing techniques, mindfulness including yoga and meditation,
and physical activity, have been shown to help counteract the stress response by decreasing SNS
(Benson, 2000; Duraimani et al., 2015; Park, Lyles, & Bau-Wu, 2014) and allow the arteries to
relax (dilate) and increase blood flow, thereby reducing blood pressure. Despite the availability
of several effective programs aimed at reducing high BP in individuals with hypertension in
general, including lifestyle and diet modifications (i.e., behavioral modification to diet and
activity levels), ADTs, education and stress reduction, meditation and paced breathing
techniques, AAs remain somewhat unaffected by these approaches often leading them to seek
alternative ways to treat hypertension beyond lifestyle modifications or ADT’s (Artinian et al.,
2008; Dennis, Markley, Johnston, Vander Wal, & Artinian, 2008; DeSimone & Crowe, 2009;
DHHS, 2012; Knox et al., 2002; Lochner et al., 2005; Svetsky et al., 1999). Given the adverse
effects that AAs have with some ADTs, challenges they experience with lifestyle modifications,
and their desire for treatment, it is important to explore possible treatments that address such
barriers.
Biofeedback, an intervention specifically designed to decrease SNS activity, may be one such
alternative approach. Available research suggests it may well serve as a useful adjunctive aid,
one that is absent of unwanted side effects of ADT’s and that may more easily overcome known
barriers to hypertension treatment in this population (Linden & Moseley, 2006). A number of
biofeedback approaches have been shown to be of value in treating hypertension; however most
of them require extensive interaction with highly trained therapists and utilize very specialized
equipment. To reduce these costs, investigators have begun to explore the utility and
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effectiveness of portable compact, self-contained biofeedback BP devices, ones that can be used
in a home setting and require minimal therapist instruction. One such device is the RESPeRATE,
which is FDA-approved for hypertension. Of note, breathing relaxation interventions, such as
that employed by the RESPeRATE, have been more effective in producing both short and long
term significant reductions in blood pressure than forms of relaxation that utilize mental meansa component of meditation (Kaushik, Kaushik, Mahajan, & Rajesh, 2006). Elliot and Izzo (2006)
provided the initial evidence of efficacy of this device in a case report. Upon using this unit,
which they termed a “Biofeedback-Assisted Breathing Relaxation” (BARB) device, a Caucasian
female was able to effectively lower her BP 17/14 mm Hg, in an 8-week period, without
unwanted side effects, and when used either alone or when combined with lifestyle modifications
or ADTs. However, follow up data collection was minimal (and the report was, of course,
uncontrolled).
Several subsequent studies with this home trainer have shown significant initial reductions in
BP, following an 8-week treatment period, that were maintained throughout the day and even up
to 6 months after usage of the BARB device (Meles et al., 2004; Rosenthal, Alter, Peleg, &
Gavish, 2001; Schein et al., 2007). The average reduction of BP in these studies was 14/8 mm
Hg, compared with control treatments of 9/4 mm Hg (p = .008 and p = .002, respectively for
systolic and diastolic BPs). The differences were independent of gender and medication status.
Recognizing the added costs of seeking treatment solely in the medical office setting has led
some investigators to explore ways for patients to apply aspects of treatment within their homes.
This research was spurred, in part, by the findings of Tilburt et al. (2008), who examined
associations between hypertension home-remedy use and self-reported adherence among a
poorly controlled hypertensive urban AA population (N = 183, drawn from the 1999-2004 Inner
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City Hypertension and Organ Damage study). Home remedy in their investigation was defined as
any non-pharmacological self-administered healing approach using everyday life items (i.e.,
herbs, spices, vegetables, over-the-counter medications, and items traditionally used for cooking
that are used to treat a variety of ailments). Participants were asked if they used home remedies
for their general health and their hypertension and if so, which ones. Home-remedy use was
found to be independently and positively associated with greater medication adherence; hence,
the idea to build upon the seeming preference by some AAs to self-treat at home. Feldman et al.
(2009) conducted a 3-arm randomized controlled trial that focused on field nurses, nurses who
work out in the field (i.e., home settings) who tested 3 strategies in African Americans to
improve hypertension management and outcomes. This study was completed in a decentralized
service setting serving a home care population. Once admitted [to the study], field nurses were
randomized to usual care (TAU), a basic, or augmented intervention condition. Nurses assigned
to the “basic” intervention provided key evidence-based reminders to home care nurses and
patients while the patient received traditional postacute home health care; nurses assigned to the
“augmented” intervention did the same as the basic intervention plus transitioning patients to an
ongoing Hypertension Home Support Program that extended support for 12 months. Patients in
both intervention groups received a home-based automated blood pressure monitor. The TAU
condition proved substantial improvements in controlling BP and created a high comparative
effectiveness threshold for future studies providing supporting for treatment of AA’s with
hypertension in the home setting.
The previous studies examining the RESPeRATE have shown significant reductions in BP.
However none of these studies has researched the effectiveness of the RESPeRATE in an AA
sample specifically or included follow up periods beyond 8 weeks (Elliot et al., 2004; Schein et
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al., 2001, 2007). The convenience and ease of operation and administration of a device like the
RESPeRATE, which at the same time helps to mitigate a number of associated barriers to
effective treatment, led us to explore whether this device could augment medical office-based
treatment and lead to further reductions in BP in AAs diagnosed with hypertension. If so, devices
like the one examined here could be more readily and easily disseminated throughout medical
clinics.
This study was thus implemented to address a number of problematic issues reviewed above,
chief among them being the previously mentioned barriers to successful hypertension treatments
in AAs by attempting to minimize the demands placed upon patients. First, the home device
selected allows patients to easily and independently complete a specially guided breathing
technique in the convenience of their own homes and at times that best fit the demands of their
schedules. This alone could potentially result in increased adherence. Second, if effective, use of
the device could reduce the frequency of physician office visits and amount and type of
medication needed, which in turn would reduce both transportation and lost wages associated
with seeking treatment and medication expenses. Third, the RESPeRATE provides individuals
with immediate feedback of proper usage, which may enhance motivation. Fourth, should
patients attain meaningful reductions in BP and the reductions remain over time, the monetary
savings resulting from reduced office visits and lowered medication costs ccould quickly offset
the moderate cost of this or similar biofeedback or relaxation units ($200-300). Fifth, the
RESPeRATE can be altered in order to collect user data, permitting researchers to examine dose
versus response analyses and study patterns of usage. Having this kind of information could be
very helpful for tailoring and adjusting treatments in the future. Finally, the efficacy of the
RESPeRATE has been proven in nearly 11 clinical trials. However, those trials were supported
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by manufactures or individuals involved with device (Mahtani, Nunan, & Heneghan, 2012).
Taken together, it seems reasonable to believe that, based on previous RESPeRATE studies, this
device could serve as an effective adjunctive aid for lowering high BP in AAs who are
hypertensive by reducing potential barriers to effective treatment as well as allowing for analysis
of real world implications of usage of the RESPeRATE, taking science one step closer to
preparing medical providers to be able to disseminate treatment much more broadly.
Method
Participants
Participants were recruited from a local urban mid-south internal medicine clinic. Medical
charts were reviewed to identify patients meeting the following inclusion criteria: between 18
and 75 years of age (CDC, 2011), prior diagnosis of hypertension by a physician (elevated
systolic BP of > 140 mmHg and diastolic BP of > 90 mmHg (James et al., 2014; WHO, 2011)
within the past 12 months but whose condition was not currently adequately controlled or had
previously experienced challenges in reducing their blood pressure in the past 12 months, as
defined by one or more of the following: self-reported limited transportation to medical clinics;
high medication costs; convenience; and low medication adherence (if on medication), < 40% of
the regimented time, as defined by categories set forth by Mazzaglia et al. (2009; high
(proportion of days covered, ≥80%), intermediate (proportion of days covered, 40% to 79%), and
low (proportion of days covered, ≤40%). Exclusion criteria included: any severe psychiatric,
medical or comorbid conditions—uncontrolled diabetes, heart disease, pregnancy, or a known
pulmonary disease, or having excessively high and uncontrolled BP, defined as either SBP above
190 mmHg, DBP above 100mmHg, or both.
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Research indicates that African Americans are at higher risk for developing hypertension
than are Caucasian and Mexican Americans, and that this is especially so for AA females (Roger
et al., 2012). Our recruitment aims, therefore, were to enroll a representative sample of AA
individuals, for whom alternative treatments had not previously worked optimally.
Procedure
A member of the research team contacted all interested and referred participants to conduct a
formal screening to determine their study eligibility, inviting all who qualified. Participants
deemed eligible, but who declined to participate, were provided with contact numbers for local
hospitals/emergency services. Individuals judged ineligible were thanked for their interest and
informed of possible treatment options at a local community health center. Nearly 100
participants were assessed for eligibility at the start of the study and 65 declined to participate.
Sixty-two participants were uninterested in participation and three participants were unable to
commit to the requirements for the study. In sum, 33 participants agreed to participate and 14
were randomized to the TAU condition and 19 to the ReSPERATE condition. At the start of the
study 14 participants were randomized to the TAU condition and 19 to the ReSPERATE. Twelve
participants remained in the TAU condition; two were removed before the EOI due to missing
appointments. Similarly, 16 participants received the ReSPERATE intervention; three were
withdrawn over the intervention period due to missing appointments. At the end of the 6-month
study period 1 additional participant was withdrawn from the TAU condition and 5 participants
from the ReSPERATE condition, leaving 33 total participants.
Participants who met full study criteria and who wished to partake in the study were
informed of the necessary commitments: an initial 1.5 hr training session on how to measure
their blood pressure accurately (administered by the medical professional on site—Physician’s
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Assistant (PA) or Nurse), psychoeducational information about high blood pressure, the
treatment rationale and components for participants, an informed consent process, and a
comprehensive battery of measures including: general demographic information, level of stress,
perceived stress (as more perceived stress has been associated with higher BP), symptoms of
anxiety and depression, medication dosage and adherence, and quality of life. All participants
were carefully followed and monitored over an 8-week period, until the end of the intervention
(EOI) period, and throughout the duration of the study. All patients received immediate posttreatment BP readings, and follow ups at 3 and 6 months. Informed consent was explained and
obtained from each participant in accordance with the “Ethical Principles of Psychologists and
Code of Conduct” (American Psychological Association, 2013), with all being informed of their
right to withdraw participation at any time without penalty. IRB approval was obtained before
commencement of the study.
During the session in which participants completed the abovementioned measures, they were
informed that they would receive monthly pre-scheduled phone calls (at select times) from
research staff to monitor their progress, answer questions, and clarify any other needs.
Participants were asked to return to the local medical clinic every 4 weeks with the hopes of
being able to retrieve adherence data (the maximum amount of data storage for the device) for
brief consultations, at which time the researchers downloaded the data from the RESPeRATE1.
The first 2 months entailed the patient education component, initial data collection, and
intervention. During months 3-6, researchers called participants once a month to monitor their
progress, answer any questions, and clarify any other needs.
At the conclusion of the study, participants completed a 5-question survey developed by the
PI to assess satisfaction with RESPeRATE. Questions addressed ease and utility of the device as
1

Technical problems precluded collection of sufficient data to permit meaningful analyses
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well as general feedback about potential improvements to the study and any other factors.
Participants received a $10 gift card upon completion of each assessment and all scheduled
intervention sessions, for a maximum of $70.
Data Safety and Monitoring. An expert interdisciplinary team of researchers, physicians,
nurses, and faculty members from the School of Public Health (SoPH) collaboratively and
consistently monitored participant progress throughout this study. Incorporating health care
providers (HCP) from the community had the added benefit of providing a larger recruitment
pool as well as truly engaging the Community in our efforts.
All identifiable information provided by participants was stored separately on a secure
database; each participant was assigned a non-identifiable subject number and the deidentification process occurred within 72 hrs of receiving confidential information. All additional
information obtained from participants was entered into a second database identified only by
participant number. Only members of the trained research team entered the data into the
database. The two databases were stored on two separate computers, backed up on separate
external hard drives that were stored on servers behind a firewall. The PI and her faculty mentor
had access to the identifiable dataset. Participant information is currently stored behind three
locked doors and a password protected computer (and a separate password protected document
on the computer).
Additionally, a three-person Data Safety and Monitoring Board (DSMB) was assembled to
ensure the safety of the participants. The DSMB was comprised of an expert in one of each of
the following areas: biofeedback, statistics, and a medical doctor. The DSMB purpose was to
identify any signal detection problems including: a pre-specified level of deterioration in blood
pressure, reaching a hypertension crisis stage of systolic blood pressure of 180 or higher or
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diastolic of 110 or higher, blood spots in the eyes, facial flushing, dizziness, severe headaches,
severe anxiety, shortness of breath, or nosebleeds, and to clearly define the steps that would have
been taken and implemented should a crisis arisen during the study; this did not occur (AHA,
2012).
Treatment Conditions. Eligible participants were assigned to 1 of the 2 below conditions
(Treatment as Usual (TAU) compared to TAU combined with the addition of the RESPeRATE),
via a free online random number generator, taking care to achieve an equal number of males and
females per condition (and balanced for age as well to the extent possible).
Control/Treatment as Usual (TAU). Much discussion has appeared in the literature about the
ethical design of control conditions. Upon a careful examination of the literature (e.g., Freedland,
Mohr, Davidson, & Schwartz, 2011; Smelt, Van der Weele, Blom, Gussekloo, & Assendelft,
2010), we determined that TAU was the most ethical and practical (pragmatic) control condition
to include, especially given the site in which this investigation was conducted—an actual
medical clinic. By design, all participants were currently receiving some type of treatment for
their high BP (chiefly medication). Participants were requested to continue their current
treatments to minimize sources of medication confounds (with concurrence of their treating
physician) and to refrain from making any adjustments, unless instructed to do so by their
treating physician. They were carefully followed, medications checked, and seen by study
medical personnel at all key assessment time points. Patients assigned to the TAU condition
were offered an opportunity to receive the RESPeRATE (described below) at the end of the
study.
Intervention/ TAU + RESPeRATE Device. The RESPeRATE is designed to systematically
shape reductions in sympathetic outflow of the autonomic nervous system, one of the key
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underlying causes of cardiovascular disease, and to promote balance between sympathetic and
parasympathetic systems. It has three main features: a breathing sensor (consisting of an elastic
band wrapped around the chest), a computerized display, and headphones. As the user inhales
and exhales, the breathing sensor and the onboard computer analyze breathing patterns and play
back two personalized guiding tones, one for inhaling and the other for exhaling. Breathing
naturally synchronizes with the tones. As an individual sits and listens to the tones, the
RESPeRATE prolongs the tones, guiding the user to slow breathing effortlessly to the desired
frequency (approximately 6 cycles per minute). This more relaxed rate of breathing is presumed
to facilitate dilation of the muscles surrounding the small blood vessels, which permits blood to
flow more freely, subsequently reducing blood pressure.
Measures
Literacy level was assessed using two questions from the International Adult Literacy and
Life Skills Survey (ALL), in order to ensure that participants understood the above-mentioned
measures. This survey was normed on both 4th and 8th graders and was designed for a 4th grade
reading level (U.S. Department of Education, 2012). Selected participants included individuals
who answered both questions correctly to ensure each had a literacy level of at least 4th grade.
No participants were screened out on this basis.
Medication usage was assessed by asking participants to self-report on 4 questions: “are you
currently taking any medication (s)?”, if so, “what are they?”, “How many times during the day
did your doctor tell you to take your medication for hypertension?”, and “what is the total
number of pills that your doctor has told you to take each day?” Possible score values for number
of medications ranged from 0 to 10. This information was used to understand how many ADT’s
people were prescribed and if the RESPeRATE was effective enough to reduce medication

13

management of HTN. Names of medications were obtained for informational purposes only.
Frequency of dosage was informative to researchers in the form of degree of HTN.
Demographic information including, age, race, gender, marital status, annual household
income, zip code, date of birth, and highest level of schooling were collected. For the purposes of
the rest of this paper, gender will refer to the gender with which they identified.
Primary Outcome Measures.
Blood Pressure. Medical staff naïve to the purposes of the study collected all BP measures to
minimize potential for bias. They used automated cuffs and adhered to the guidelines established
by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (James et al., 2014). Participants were asked to enter the office/laboratory and sit
calmly for 5 min and the average of 3 BP readings (with 2 -3 min between each reading) were
taken to acquire baseline values for systolic and diastolic BP.
Secondary Outcome Measures. Participant’s levels of psychosocial stress were examined
through the usage of several measures:
Beck Depression Inventory–II (BDI–II). The BDI-II (Beck, Steer, & Brown, 1996) is a 21item self-report instrument that is used to measure the severity of depressive symptoms in
diagnosed patients as well as to detect possible depression in a normal population, as defined in
the DSM-5 (including suicidality). The BDI–II has high internal reliability (Cronbach’s alpha is
.92 for clinical patients and .93 for non-clinical individuals) and test-retest reliability (r = .93).
Most items on the BDI-II are rated on a 4-point scale ranging from 0 to 3, with 3 reflecting the
more severe level. Several items have seven response options to discern differences in behavior
or motivation. The BDI-II is scored by adding the ratings for the 21 items. Possible score values
range from 0 to 63. Scores from 0 to 13 reflect minimal depression symptoms, 14 to 19 mild
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levels of depression symptoms, 20-28 moderate levels of depression symptoms, and 29-63 severe
depression symptoms.
The Beck Anxiety Inventory (BAI). The BAI (Beck, Steer, & Brown, 1993) is a 21-item
scale that measures the severity of self-reported anxiety in adults and adolescents. It consists of
descriptive statements of anxiety symptoms that are rated on a 4-point scale with the following
correspondence: “Not at all” (0 points); “Mildly; it did not bother me much” (1); “Moderately; it
was very unpleasant, but I could stand it” (2); and “Severely; I could barely stand it” (3). The
BAI was designed to reduce the overlap between depression and anxiety scales by measuring
anxiety symptoms shared minimally with those of depression. The BAI has high internal
reliability ranging from .92 to .94 for adults and .75 test-retest reliability. The BAI total score is
the sum of the ratings for the 21 symptoms. Each symptom is rated on a 4-point scale ranging
from 0 to 3. The higher the BAI score the more severe the individual’s anxiety is. Possible score
values range from 0 to 63. Scores from 0 to 9 reflect minimal anxiety symptoms, 10 to 16 mild
levels of anxiety symptoms, 17-29 moderate levels of anxiety symptoms, and 30-63 severe
anxiety symptoms.
The Perceived Stress Scale-10 (PSS-10). The PSS, which has three versions [a 4-item
(PSS4), 10-item (PSS10) and 14-item (PSS14)], was used to assess stressful events (Cohen &
Williamson, 1988). The PSS10, a self-report instrument that has been used to measure the degree
to which life situations are appraised as stressful and the extent of control participants perceive
they have over such situations, was used in this study. Each item asks about participants’
thoughts and feelings during the past month (Cohen, Kamarck, & Mermelstein, 1983). In each
question, participants are asked how often they felt or thought a certain way. Items are rated on a
5-point scale and responses range from 0 (never) to 4 (very often). Scores are obtained by

15

reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1, 4 = 0) to the four positively stated items (4, 5,
7, 8) and then summing across all scale items. Total scores range from 0–40, with higher scores
indicating greater perceived stress. The internal reliability of the PSS10 has been reported as .78
(Cohen & Williamson, 1988). In more recent studies with AAs, the PSS4 has demonstrated
higher internal reliability, α = .85 and α = .84 (Artinian et al., 2006; Dennis et al., 2008). Despite
the higher internal reliability, the PSS4 is generally used during interviews that assess briefer
measures of perceived stress. The PSS10 inquires in greater detail about an individual’s
perception of stress and has slightly higher internal reliability than the PSS14.
Quality of Life Scale (QOLS). The Quality of Life Scale (QOLS; Flanagan, 1978) is a 16item self-report measure (originally a 15-item measure) that was used to assess individual’s
quality of life across several domains: material and physical well- being, relationship with others,
social, community, and civic activities, personal development and fulfillment, and recreation.
Responses were scored on a 7-point Likert scale and included: "delighted" (7), "pleased" (6),
"mostly satisfied" (5), "mixed" (4), "mostly dissatisfied" (3), "unhappy" (2), "terrible" (1).
Flanagan’s original 15-item QOLS did not report internal consistency reliability (Cronbach's
alpha); however, the first study of 240 American patients with chronic illness indicated that the
15-item QOLS satisfaction scale was internally consistent (α = .82 to .92) and had high test-retest
reliability (r = 0.78 to r = 0 .84). Researchers have reported similar reliability estimates for the
16-item scale (Anderson & Burckhardt, 1999; Burckhardt & Anderson, 2003; Burckhardt,
Anderson, Archenholtz, & Hägg, 2003; Burckhardt, Archeholtz, & Bjelle, 1992; Burckhardt,
Woods, Schultz, & Ziebarth, 1989). The QOLS is scored by adding the scores for all items. The
greater the QOLS score, the higher the quality of life. Possible score values range from 16 to 112
to reflect overall quality of life. Average total score for healthy populations is about 90.
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Adherence Measures. Upon special request it is possible to have the manufacturer enable the
RESPeRATE devices to track actual measures of use. However, a variety of technical problems
occurred during attempts to collect this data, rendering us unable to have sufficient data for
analysis.
Analysis
A power analysis, using OpenEpi with an alpha level of .05 and a power of .80, was
conducted to determine the appropriate number of participants needed in each study condition in
order to obtain meaningful statistical results. Assuming an equal number of participants per
condition, a total sample size of 33-36 participants was desired, 17-18 per group. A mixed
repeated measures model (MRMM) was conducted to determine the temporal relationship
between the IV and DV variables. This analysis was selected because it accounted for within
person variance, permitting a better understanding of the intra-correlations between changes in
BP over time. A MRMM explains the variance by the individual error term, which better
represents the internal structure of the data. Changes in relevant independent variables, over a 6month period, were used to predict changes in BP over time. Sensitivity analyses revealed that
random effects were too unstable for the model to withstand. Therefore, subsequent growth
curve analyses and variations of regressions were completed. The best suited model of fit was a
standard multiple regression model. The statistical programming software package R was used to
perform all analyses. All IV and DV variables were included in the preliminary model with
subsequent models removing non-significant predictor variables. The most suitable models
included independent variables: gender, SES, age, and education level. Preliminary analyses
were conducted to ensure no violations of the assumptions existed with respect to normality,
linearity, multicollinearity, and homoscedasticity. No psychological measures were able to be
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included in the overall model due to the small sample size, reducing the degrees of freedom
available to the model. However, as this was a small-scale pilot investigation, t-tests were used to
explore mean group difference for psychological variables at all key time points by conditions
and gender. Tables 3-6 summarize changes in total scores and Cohen’s d for all independent
psychological measures from baseline to EOI, EOI to three months, and three months to six
months, respectively, broken down by condition gender.
Results
Participants Completing the Trial
Figure 1, appearing on the next page, provides a summary of patient recruitment, selection,
and participation rates at each stage of this pilot investigation, using the flow diagram
recommended by the Consolidated Standards of Reporting Trials Group (www.consortstatement.org).
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Enrollment

Assessed for eligibility (n=98)

Excluded (n=65)
 Not meeting inclusion criteria (n=0)
 Declined to participate (n=62)
 Other reasons (n=3)

Randomized (n=33)

Allocation
Allocated to TAU (n=14)
 Received allocated intervention (n=12)
 Did not receive allocated intervention
(withdrawn by PI due to missing
appointments) (n=2)

Allocated to RESPeRATE intervention (n=19)
 Received allocated intervention (n=16)
 Did not receive allocated intervention
(withdrawn by PI due to missing
appointments) (n=3)

Follow-Up
Lost to follow-up (unable to complete make
scheduled appointments, participation
withdrawn (n=1)
Discontinued TAU (n=0)

Lost to follow-up (conflicting work schedule)
(n=5)
Discontinued intervention (n=0)

Analysis
Analysed (n=12)
 Excluded from analysis (n=0)

Analysed (n=16)
 Excluded from analysis (n=0)

Figure 1. Consort reporting of trials flow diagram.
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Table 1 below provides baseline demographic characteristics for the participants completing
this pilot trial.
Table 1
Baseline Characteristics of Patients Completing the Study

Baseline Systolic Blood Pressure
Male
Female
Baseline Diastolic Blood Pressure
Male
Female
Age
Male
Female
Gender
Male
Female
Number of HBP Medications
Male
Female

Intervention
n=16

Control
n=12

137.33+5.89
133.00+13.34

131+10.96
129.67+2.08

88+4.73
80+10.26

86+13.04
76+8.72

60+8.97
60+10.11

56.77+7.82
47.67+19

6
10

9
3

1.50+1.52
1.60+.70

3.55+2.67
1.67+2.10

Overall Model
A standard multiple regression was used to determine if use of the home-based biofeedback
device would significantly predict changes in blood pressure-both systolic and diastolic-from
baseline to the end of the intervention period (8weeks). A four predictor model explained 98% of
the variance (R2 = .98, F (22,85) = 215.7, p<. 001). Findings indicated that gender, age, SES,
and education level each uniquely and significantly predicted reductions in systolic blood
pressure, respective of order of weight in the model (see Table 2).
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Table 2
Standardized Coefficients and Associated T-Statistics
Variable
Systolic β(SE)
Age
-.26 (-6.52)**
Gender (Male)
8.35 (12.63)**
SES
<10,000
29.23 (1.19)***
$30,000-$39,999
6.31 (1.48)***
$40,000-$49,999
2.73 (.92)**
$75,000-$99,000
5.73 (4.99)***
Education
Doctorate Degree
9.43 (1.48)***
High School
7.62 (1.09)***
Masters
-6.25 (.84)***
Professional Degree
4.86 (4.10)***
Some College
5.13 (.95)***
Voc. Training
9.48 (3.27)**
Note. *p <.05. **p <.01. ***p <.001

t
---

Diastolic
-13.74 (3.24)
--

t
-3.20*
--

--

--

24.41
4.26
2.97
1.15
6.35
6.99
-7.47
4.10
5.37
2.90

Overall, gender, specifically being a female, significantly predicted reductions in systolic
blood pressure at the end of the intervention (β = 8.34, SE = .66, t (28) = 12.63, p<.001).
Similarly, age significantly predicted successful reductions in systolic BP at the end of the
intervention (β = -.26, SE = .04), t (28) = -6.52, p<.001). Also, contributing predictor variables
included SES and education level. For additional information on categorical breakdowns of SES
and education level, see Table 2.
Baseline to Efficacy Endpoints. Primary endpoint analyses using a standard multiple
regression were employed to test if those using the home-based biofeedback device would
significantly predict changes in blood pressure-both systolic and diastolic-from baseline to the
end of the intervention period (8weeks). A significant reduction in systolic blood pressure was
found from baseline to the EOI in the intervention condition (β = .19, SE= .02, t (28) = 7.69,
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F(22,85) = 215.7, p <.001). There were statistically significant differences between baseline
systolic blood pressure reductions to the EOI systolic blood pressure reductions
(β = .19, SE = .03, t (28) = 7.57, p <.001) and from baseline to three months in systolic blood
pressure reductions in the control group (β = -1, SE = .06, t (28) = -15.51, p <.001) as well.
There were no significant reductions in diastolic blood pressure at any key follow up time points.
Systolic Blood Pressure in the RESPeRATE Group.
Three months. We found statistically significant reductions in systolic blood pressure from
baseline to three months in the intervention group compared to TAU (β = .14, SE = .04, t (28) =
3.47, p <.001).
Six months. Systolic blood pressure reductions from baseline to six months was significant in
the RESpeRATE group (β = .36, SE = .04, t (28) = 9.09, p <.001) compared to the TAU group.
Diastolic Blood Pressure. We found no significant reductions in diastolic blood pressure at
any key study time points for either condition. As such, no overall predictors or values were
reported.
Psychological Measures. Though psychological measures were not able to be included in the
overall model, t-tests were used to explore mean group differences for all measures at all key
time points by conditions and gender. No significant findings emerged for any mean group
scores in psychological measures at any key time points. However, small, moderate and large
effect sizes were seen. Tables 3-5 summarize changes in total scores and Cohen’s d for all
independent psychological measures from baseline to EOI, EOI to three months, and three
months to six months, respectively, broken down by condition and gender. The relationship for
baseline to the EOI changes in BAI and BDI group difference scores for TAU versus the
intervention and for males versus females within each condition met criteria for the convention
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of small and large effect sizes at baseline for BDI and at the EOI for BAI, (d = .80 and d = .46;
Cohen’s 1998), respectively. Examining group differences in scores from EOI to three months
by condition and gender revealed moderate and large effect sizes, respectively, for changes in
BDI and QoL total scores in the TAU condition (d = .56 and d = .91) and moderate effect sizes
(d = .75, and d = .56) for BDI and PSS scores. Changes in group differences by condition and
gender from three months to six months in BDI scores in the TAU condition exceeded Cohen’s
(1998) convention for moderate effect sizes (d = .58) and large effect sizes in the intervention
condition (d = .95). Finally, the relationship for baseline to six month changes in group
differences in BDI and QoL scores for males versus females within the TAU condition met
criteria for the convention of small and moderate effect sizes at six months for BDI and QoL, (d
= .58 and d = .26). Examining group differences in scores from baseline to six months in the
intervention group by gender revealed a large effect size for changes in females in the
intervention group (d = .94).
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Table 3
Changes in Independent Variables from Baseline to End of Intervention (EOI)
Males
M(SD)
(n = 9)

Control (n = 12)
BAI Total M(SD)
Baseline
4.00 (3.57)
EOI
5.06 (4.40)
BDI Total M(SD)
Baseline
6.44 (3.85)
EOI
5.37 (5.20)
PSS Total M(SD)
Baseline
18.00 (2.65)
EOI
3.31 (.83)
QoL Total M(SD)
Baseline
84.33 (12.01)
EOI
91.31 (10.38)
Intervention (n = 16)
BAI Total M(SD)
(n = 6)
Baseline
7.17 (10.87)
EOI
5.06 (4.40)
BDI Total M(SD)
Baseline
8.33 (6.59)
EOI
5.37 (5.20)
PSS Total M(SD)
Baseline
18.83 (2.71)
EOI
3.31 (.83)
QoL Total M(SD)
Baseline
84.00 (16.80)
EOI
91.31 (10.38)
*small (0.2) ** medium (0.5) and ***large (0.8)
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Females
M(SD)
(n = 3)

Cohen’s d

4.33 (5.86)
3.33 (3.06)

-.07
.46*

8.88 (11.55)
5.10 (5.98)

-.28
.05

22.00 (1.73)
16.60 (4.88)

-1.79
-1.13

87.67 (17.16)
89.40 (14.03)

-.23
.15

(n = 10)
4.44 (4.00)
3.33 (3.06)

.33*
.46*

4.22 (2.91)
5.10 (5.98)

.80***
.05

18.33 (3.50)
16.60 (4.88)

.16
-.88

95.33 (8.27)
89.40 (14.03)

-.86
.15

Table 4
Changes in Independent Variables from EOI to Three Months
Males
M(SD)
(n = 9)

Control (n = 12)
BAI Total M(SD)
EOI
5.06 (4.40)
Three Months
2.66 (2.87)
BDI Total M(SD)
EOI
5.37 (5.20)
Three Months
4.78 (4.38)
PSS Total M(SD)
EOI
3.31 (.83)
Three Months
16.33 (2.00)
QoL Total M(SD)
EOI
91.31 (10.38)
Three Months
97.11 (15.91)
Intervention(n = 16)
(n = 6)
BAI Total M(SD)
EOI
5.06 (4.40)
Three Months
4.15 (3.06)
BDI Total M(SD)
EOI
5.37 (5.20)
Three Months
8.50 (6.32)
PSS Total M(SD)
EOI
3.31 (.83)
Three Months
18.83 (3.87)
QoL Total M(SD)
EOI
91.31 (10.38)
Three Months
80.67 (14.05)
*small (0.2) ** medium (0.5) and ***large (0.8)
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Females
M(SD)
(n = 3)

Cohen’s d

3.33 (3.06)
3.00 (3.46)

.46*
-.11

5.10 (5.98)
2.67 (3.06)

.05
.56**

16.60 (4.88)
19.67 (4.16)

-1.13
-1.02

89.40 (14.03)
84.33 (12.06)
(n = 10)

.15
.91***

3.33 (3.06)
4.89 (4.55)

.46*
-.19

5.10 (5.98)
4.00 (5.72)

.05
.75**

16.60 (4.88)
16.67 (3.91)

-.88
.56**

89.40 (14.03)
96.11 (5.95)

.15
-1.43

Table 5
Changes in Independent Variables from Three Months to Six Months
Males
M(SD)
(n = 9)

Control (n = 12)
BAI Total M(SD)
Three Months
2.66 (2.87)
Six Months
2.67 (3.12)
BDI Total M(SD)
Three Months
4.78 (4.38)
Six Months
4.44 (4.72)
PSS Total M(SD)
Three Months
16.33 (2.00)
Six Months
17.00 (2.70)
QoL Total M(SD)
Three Months
97.11 (15.91)
Six Months
91.50 (14.83)
Intervention (n=16)
(n = 6)
BAI Total M(SD)
Three Months
4.15 (3.06)
Six Months
2.33 (1.86)
BDI Total M(SD)
Three Months
8.50 (6.32)
Six Months
8.17 (8.08)
PSS Total M(SD)
Three Months
18.83 (3.87)
Six Months
18.50 (2.17)
QoL Total M(SD)
Three Months
80.67 (14.05)
Six Months
84.17 (12.35)
*small (0.2) ** medium (0.5) and ***large (0.8)
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Females
M(SD)
(n = 3)

Cohen’s d

3.00 (3.46)
2.67 (2.08)

-.11
.00

2.67 (3.06)
2.33 (2.08)

.56**
.58**

19.67 (4.16)
20.33 (3.06)

.56**
-1.02

84.33 (12.06)
88.00 (12.17)
(n = 10)

.91***
-1.15

4.89 (4.55)
3.55 (2.92)

-.19
-.50

4.00 (5.72)
2.55 (2.28)

.75**
.95***

16.67 (3.91)
18.33 (5.98)

.56**
.04

96.11 (5.95)
96.33 (3.94)

-1.43
-1.33

Table 6
Changes in Independent Variables from Baseline to Six Months
Males
M(SD)
(n = 9)

Control (n = 12)
BAI Total M(SD)
Baseline
4.00 (3.57)
Six Months
2.66 (3.12)
BDI Total M(SD)
Baseline
6.44 (3.85)
Six Months
4.44 (4.72)
PSS Total M(SD)
Baseline
18.00 (2.65)
Six Months
17.00 (2.70)
QoL Total M(SD)
Baseline
84.33 (12.01)
Six Months
91.50 (14.83)
Intervention (n = 16)
BAI Total M(SD)
(n = 6)
Baseline
7.17 (10.87)
Six Months
2.33 (1.86)
BDI Total M(SD)
Baseline
8.33 (6.59)
Six Months
8.17 (8.08)
PSS Total M(SD)
Baseline
18.83 (2.71)
Six Months
18.50 (2.17)
QoL Total M(SD)
Baseline
84.00 (16.80)
Six Months
84.17 (12.35)
*small (0.2) ** medium (0.5) and ***large (0.8)
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Females
M(SD)
(n = 3)

Cohen’s d

4.33 (5.86)
2.67 (2.08)

-.07
.00

8.88 (11.55)
2.33 (2.08)

-.28
.58**

22.00 (1.73)
20.33(3.06)

-1.79
-1.15

87.67 (17.16)
88.00 (12.17)

-.23
.26*

(n = 10)
4.44 (4.00)
3.55 (2.96)

.33*
-.50

4.22 (2.91)
2.56 (2.30)

.80***
.94***

18.33 (3.50)
18.33 (5.98)

.16
.03

95.33 (8.27)
96.33 (3.94)

-.86
-1.33

Discussion
In the first report released by Joint National Committee, in 1997, hypertension was defined
solely on the basis of diastolic blood pressure, with the cutoff being > 90mm Hg (James et al.,
2014); systolic blood pressure was not taken into account. It has long been thought that systolic
hypertension, then termed isolated systolic hypertension (ISH), was unavoidable due to ageing
and was exacerbated by hardening of arterial walls related to plaque buildup and subsequent loss
of elasticity of the arterial walls. It was further assumed that diastolic blood pressure either
stabilized or declined over time as a result of peripheral resistance, the resistance of the arteries
to blood flow (Burt et al., 1995). When arteries constrict, resistance increases; as they dilate,
resistance decreases and blood flow increases. Peripheral resistance is a function of the internal
vessel diameter, vessel length, and blood viscosity. Over time, as researchers came to realize that
other parameters needed consideration in order to more fully and accurately diagnose HTN, they
found it was critically important to consider SBP as well in arriving at a diagnosis of HTN (Izzo,
Levy & Black, 2000; Lloyd-Jones et al., 2000). Overlooking an elevated SBP can lead to a
misclassification of blood pressure grade and contribute to untreated HTN. Just like traditionally
classified HTN, high SBP can lead to long-term damage that is irreversible. Lloyd-Jones et al.
(2000) were able to correctly classify 96% of individuals into the correct blood pressure stage
when using subjects' systolic blood pressure values alone, but their classification accuracy
decreased to 68% when using subjects' diastolic reading alone. Izzo, Levy, and Black (2000)
similarly identified the overall importance of systolic blood pressure in older Americans,
questioning the significance of diastolic blood pressure altogether as a determinant for a
hypertension diagnosis. Regardless of the qualifying diagnostic cutoffs, systolic blood pressure
continuously rises between the ages of 30-84 years, with the arterial walls developing plaque
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build-ups along the way. Diastolic blood pressure, however, has a varying pattern with ageing,
increasing until the fifth decade and slowly decreasing from the age of 60 to at least 84 years of
age (Franklin, 1999). Drawing upon these findings, a case can be made for an accessible
intervention that aids in the reduction of SBP and that is available for individuals struggling with
traditional behavioral and medical interventions.
In the current exploratory study, we examined the efficacy of a home-based biofeedback
intervention, delivered by the RESPeRATE, in a sample of AAs who were hypertensive. We
found that utilization of the RESPeRATE in AAs diagnosed with hypertension over an eight
week, 3-month, and 6-month period was effective in reducing systolic blood pressure with
respect to TAU. This same device, however, was not effective in reducing diastolic blood
pressure at those same key follow-up time-points. If ISH is a key component in controlling
overall hypertension, future research needs to devote greater attention towards interventions
(medical and other) for reducing it. Furthermore, given the inevitable rise in SBP (and the
fluctuating course of DBP), devices like the RESPeRATE could prove to be a helpful tool for
reducing SBP for all populations, and perhaps more specifically for those whose medications and
lifestyle/diet modifications have not been sufficient.
Hypertension and cardiovascular disease are nearly equally contribute contributing to the
growing cost of healthcare. If the findings from this pilot study hold upon replication,
incorporating relatively low-cost, home-administered devices for individuals who have tried
other interventions with limited success (i.e., the RESPeRATE), may yield favorable cost-benefit
returns. Moreover, as home-administered devices can help to break down many treatment
barriers for individuals with diminished resources, the impact for our overall health-care system
could yield large-scale reductions in a number of ways over time: health care costs, burden on
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medical providers, and less reliance on pharmaceutical interventions (Artinian, Washington,
Flack, Hockman, & Jen, 2008; Dennis et al., 2008; Knox et al., 2002; Horowitz et al. 2004;
Merritt et al., 2004).
Our results are consistent with past studies in which the efficacy of the RESPeRATE was
shown for reducing BP (Elliot et al., 2004; Mahtani et al., 2012; Meles, 2004). Our work helps
extend these findings to minority populations, specifically to AAs so diagnosed with
hypertension and, while being treatment adherent to medication, have not experienced optimal
results. Unlike previous studies, we did not find significant reductions in DBP at any key time
points.
Socioeconomic status, age, gender and education level also significantly predicted reductions
in systolic blood pressure at the end of our eight-week intervention and at 3 - and 6-month follow
up. Socioeconomic status-a multi-faceted construct that is often measured by proxy of income,
education, and/or occupation-often serves as a powerful predictor for health disparities and
health-related outcomes (WHO, 2008), specifically in an AA sample (Non, Gravlee, & Muligan,
2012; Ostchega, Yoon, Hughes, & Lewis, 2008; Rooks et al., 2008). In the current study, SES
was based on income, which was further broken down into ten distinct categories (see Table 2).
Overall, research suggests a consistent strong inverse relationship between SES and health
disparities (Williams, Mohammad, Leavell, & Collins, 2010). Individuals who fall into higher
SES brackets experience overall fewer health disparities relative to their lower SES counterparts.
Specifically, rates of hypertension and cardiovascular disease are higher among lower
socioeconomic status populations (Steptoe & Kivimaki, 2013). The numbers of cases of
hypertension are even more alarming among African Americans versus other minority groups.
Some of the most robust associations of low SES and specific health disparities, specifically
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hypertension, occur for African Americans (Steptoe & Kivimaki, 2013). This relationship has
been demonstrated in studies in which education was used as a proxy for SES. Non and
colleagues (2012) explored the associations of genetic ancestry and education with BP variation
among African Americans in the Family Blood Pressure Program. Education level was divided
into two groups – high school degree or greater versus less than a high school degree. Individuals
with a high school degree or greater were found to display significantly greater reductions in
overall BP. These authors found further that education significantly predicted BP variation in
AAs (b = −0.51 mm Hg per year additional education; p= .001). Brummett et al. (2011)
conducted a large scale cross-sectional study with over 15,000 young adult AA males and
females ages 24-35 that permitted them to investigate the association between socioeconomic
status and hypertension. Socioeconomic status was defined by educational level and household
income. Similar to other researchers, they found an inverse relationship between education and
BP, specifically for SBP, such that higher household income was associated with lower SBP.
Older male AAs evidenced higher SBP even after controlling for various covariates (cardiac
medication use, BMI, waste circumference, physical exercise, alcohol consumption, and
smoking behavior).
The Framingham Heart Study, a large-scale longitudinal cohort study, documented that blood
pressure increases with age (Franklin, 1999; O’Rourke, 1990). The abovementioned well known
study began in 1948 by recruiting 5,209 men and women between the ages of 30 and 62 from the
town of Framingham, Massachusetts. Participants were asymptomatic for cardiovascular disease,
heart attack, or stroke when the study began. Since 1948, numerous offspring cohorts have been
added: an offspring cohort was added to the study in 1971, the Omni Cohort in 1994, a third
generation cohort in 2002, a new offspring spouse cohort in 2003, and a second generation Omni
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cohort in 2003. Findings from the present study similarly point to age as a factor in predicting
higher BP, as baseline BP was higher in older participants, and it served as a predictor for
efficacy of the RESPeRATE. Given that the rates of hypertension are higher in AAs than CAs,
the current study results are promising and indicative of the need for further research in this area.
Investigating the effects of a home-based biofeedback or similar type intervention delivered in a
medical setting and targeted at this population, in part to reduce the overall health care costs but
more importantly to provide aid to a population so in need and seeking assistance, appears to
warrant further exploration.
Although BP changes throughout a person’s life as a function of gender and decade of life,
gender remains a constant and robust predictor. Similar to previous findings, the women in our
study displayed lower baseline BP readings as well as lower readings at all key time points.
More importantly, the RESPeRATE was effective in significantly reducing systolic blood
pressure in women at all key time points. The mechanisms involved in producing BP differences
by gender are not fully understood. The limited information comes from studies examining
androgens and renal salt processing (Maranon & Reckelhoff, 2013; Reckelhoff, 2001;
Richardson, Freedman, Ellison, & Rodriguez, 2013). It may be the case that the lack of
androgens reduces sodium handling in the kidneys, which protects against both early and later
hypertension. Further support for this proposed mechanism comes from research showing overall
BP increases in women who have had an ovariectomy (Pechere-Bertschi & Burnier, 2004). It
could be that many of the women in our study had not yet experienced medical procedures that
removed the protective sodium absorption hormones, thereby reducing the renal issues related to
salt absorption.
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One purpose of this study was to examine the impact of hypertension on an individual’s
overall psychological functioning. Findings from this study suggest meaningful clinical
implications evidenced by the varying effect sizes seen by the mean group differences examined
by condition and gender at previously mentioned key time points. The small effect size seen in
mean group differences for BAI scores from baseline to EOI could be the result of enrolling in a
clinical trial. However, given this small effect size this is very easily as likely to be anxiety
related to white-coat syndrome that reduced as participants became less anxious after the initial
visit. It could be that they developed an understanding of what was expected of them and what
would happen at each visit (Cobos, Haskard-Zolnierek, & Howard, 2015). Similarly, group
differences from EOI to three months yielded moderate to large effect sizes related to BDI, QoL,
and PSS. As one’s health profile improved over this timeframe, it is likely that these individuals
not only felt better physically but also began to experience the world in a less stressful manner,
which in turn led to lower BDI scores and overall improved QoL. Similarly, changes in mean
group score differences from three months to six months in both conditions produced moderate
to large effect sizes for BDI scores. Notably, the most consistent and larges effect sizes were
seen in mean group differences for BDI scores. This strong positive relationship has been
extensively demonstrated in studies with participants experiencing other chronic medical
conditions (Gotlieb et al., 2004; Mendes de Leon et al. 2015; Taylor et al., 2015). In accordance
with previous research, the effect sizes found in this study highlight the impact of physical wellbeing and psychological experiences and the need for further exploration of these aspects.
Furthermore, because effect sizes were moderate to large not only for conditions but also by
gender, it is possible that the renal renal processing of sodium plays a large role in this effective
intervention. As people age, renal functioning worsens by gender.
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Future Directions, Limitations, and Conclusions
In an area of research that seeks to understand such intricate and complex and not always well
defined topics such as hypertension, race, and SES, there are countless directions to pursue and
unanswered questions to address. Here we focus on what we believe to be some of the more
important avenues including moving from a pilot study to a larger sample size and the
psychological impact of hypertension. We performed this pilot study to provide sufficient
preliminary data to determine the feasibility and logistics of a more definitive study. Because our
sample size was small, the statistical models were not able to withstand inclusion of all of the
psychological measures that were obtained. Given the limited sample size and the exploratory
nature of this study, it is possible that our statistical model could have been over specified.
However, after removing education from the predictor variables (due to multicollinearity with
SES) and re-conducting our analyses, the overall model remained statistically significant, R2 =
.92. A larger sample size would have permitted greater degrees of freedom, increasing the
statistical power to conduct additional analyses. From those models, a greater degree of
information might have been ascertained related to the psychological impact(s) of hypertension
in an African American population. Therefore, one obvious next step is to conduct a larger-scale,
more well-controlled evaluation of the efficacy of the RESPeRATE or similar devices for
enhancing treatment of hypertension. Though there was sufficient power to substantiate some of
the findings for the current study, a study with a larger sample size would be needed to better
understand the impact the RESPeRATe might have in AAs diagnosed with hypertension. See
Figure 1 for a detailed outline of patient flow and attrition. Similarly, it is possible that with a
larger sample size significant reductions in diastolic BP could be detected.
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Diet, exercise, and sodium intake, among many other health-related behaviors, are associated
with hypertension (Bacon, Sherwood, Hinderliter, & Blumenthal, 2004). Less well researched is
the psychological effect of hypertension. The body of literature addressing the adverse effects of
stress on the body is vast, with mixed conclusions regarding the association of psychological
effects of stress and hypertension (Carroll, Phillips, Gale & Batty, 2010; Gasperin et al., 2009;
Linden & Moseley, 2006; Patten et al., 2009; Rutledge & Hogan, 2002). Although sodium intake
is associated with high blood pressure, some individuals are able to consume sodium without
adverse effects (i.e., hypertension). In a meta-analysis, Hermansen (2010) found that sufficient
intake of potassium and calcium, rather than simply reducing sodium, could be one way to
prevent high BP. This finding could be pursued in future studies. Finally, given the known
consequences of stress on the body and the mind-body connection, the time may be ripe to begin
exploring the utility of what has been labeled the “third wave” of cognitive behavioral therapy,
which includes a focus on mediation, mindfulness, and acceptance (Hayes, 2004). Whether these
newer treatments will prove of value for diverse populations, such as African Americans who are
hypertensive, remains relatively unknown.
Finally, working with a population that historically has had- and continues at present to havemany barriers for receiving effective hypertension treatment presented many unique challenges.
Of the nearly 100 participants initially recruited for this study, approximately 70 expressed
interest, with the resulting number of enrolled participants who actually completed the study
being much less. Transportation-related barriers or simply loss of interest when they learned of
the commitments necessary for enrollment likely accounted in part for the attrition over time.
Also, working within a medical practice versus a college clinic or laboratory presented some
unique challenges. For example, participant’s work schedules created conflicts with study
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appointments. For low income individuals needing to take time off or time-away from an income
producing job was not always an option. Due to missing appointments, researchers were forced
to withdraw people from the study despite their desire to continue. More importantly, the
ReSPERATE device only holds up to thirty days of data storage. Therefore, if a participant
wanted to reschedule for a day that fell outside of the 30-day range, they had to be withdrawn
from the study. The devices used in this investigation had to be altered in order to permit
adherence data to be collected. A number of the devices were acquired from the company who
developed the RESPeRATE, but along the way the ownership changed, with us purchasing the
remaining needed units from another vendor. Various technical problems occurred along the
way, mainly due to unstable and incompatible cable connections, resulting in adherence data
loss. Once the developing company sold their product line, we were no longer able to obtain
support for the devices purchased earlier2. Despite these study limitations, we believe our
findings substantiate the need for further research in this area with devices of this type and
support pursuit of larger-scale, more well-controlled clinical trials, with more extended follow
up, particularly with respect to AA’s who are hypertensive.

2

Previous researchers who had worked with device were contacted and provided help as they could.
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APPENDIX A
Consent to Participate in a Research Study
Enhancing Treatment for High Blood Pressure in African Americans
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH?
You are being invited to take part in a project that is comparing various procedures for reducing
high blood pressure in individuals who are African American. You are being invited to take part
in this research study because you are between 18 and 75 years of age, have previously been
diagnosed as hypertensive by a physician (elevated systolic BP of >140mmHg and diastolic BP
of > 90 mmHg) within the past 12 months and your condition is not currently controlled or you
have previously experienced challenges in reducing your blood pressure in the past 12 months,
as defined by one or more of the following: self-reported limited transportation to medical
clinics, high medication costs, convenience, low medication adherence (if on medication), <40%
of the time that your doctor asked you to take the medication. If you volunteer to take part in this
study, you will be one of about 75-90 people to do so in Memphis.
WHO IS DOING THE STUDY?
The person in charge of this study is Ms. Paige Frankfurt (Lead Investigator) who is an advanced
doctoral student in clinical psychology at the University of Memphis Department of Psychology.
Dr. Frank Andrasik, Distinguished Professor and Chair of the Department of Psychology, is
guiding her in this research. There may be other people on the research team assisting at different
times during the study, as well as staff at various medical offices.
WHAT IS THE PURPOSE OF THIS STUDY?
By doing this study, we hope to learn if a brief form of educational counseling combined with a
special home-based biofeedback device, called the RESPeRATE, can help individuals like
yourself gain better control of your high blood pressure.
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS STUDY?
Participants will not be eligible to participate if their blood pressure is presently under control,
they are being treated for or have severe psychiatric disorders, a history of stroke, heart attack or
heart failure, kidney and renal failure or disease, chronic Type I or II Diabetes Mellitus, severe
asthma, morbid obesity, pregnancy, and recent surgery that could significantly affect blood
pressure or previously mentioned conditions.
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT
LAST?
The research procedures will be conducted at The University of Memphis Center for Behavioral
Medicine (400 Innovative Drive) as well as at Midtown Internal Medicine (1533 Union Avenue),
a Methodist Healthcare facility in Memphis, TN. Should you agree to participate in this study,
you could need to come to one of these locations between 4 and 9 times during the study, plus an
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initial meeting that may last up to 90 minutes. Although the amount of time will vary according
to the treatment you receive, the maximum amount of time will be about 11 hours over the next 6
months.
WHAT WILL YOU BE ASKED TO DO?
If you meet eligibility criteria and wish to partake in the study, you will be informed of the
commitments: an initial training session (at the medical clinic) on how to measure your blood
pressure accurately (administered by the PI and one medical professional on site—PA or Nurse),
psychoeducational information for the treatment rational and components for participants, an
informed consent process, and a comprehensive battery of measures including: general
demographic information, level of stress, perceived stress (as more perceived stress has been
associated with higher BP), symptoms of anxiety and depression, medication dosage and
adherence, and quality of life. If relevant, you could be asked to complete a three day adherence
measure in which you will be asked to report on how well and consistently you follow the
management plan developed with your Health Care Provider (HCP).
The study will be comparing 2 different conditions: one being a waiting list that will involve you
carefully tracking my current treatment (#1) and another involving the addition of specific
educational strategies for improving my blood pressure control and an electronic breathing
device to facilitate you becoming more relaxed and that may help provide further benefit (#2).
You will be assigned on a random basis to the one of the 2 conditions. This means you will have
a 1 in 2 chance of being assigned to any one of the above conditions.
You will be required to complete a number of inventories and have your blood pressure taken at
the beginning of the project, with the inventories and blood pressure measurements being
repeated at 2,3,4,5, and 6 months. You will be asked to keep a record of your current treatments
(medications, etc.) throughout the entire project, no matter what condition you are assigned.
If you are assigned to the first condition you will continue any treatment that you are already
doing. If you are not doing anything, you will continue doing that.
If you are assigned to the second condition you will need to meet with one of the researchers for
training in how to maximize your current treatment. This will involve in person meetings and
several brief telephone calls. You also will be provided with a home breathing relaxation device
and trained in how to use it properly. You will need to meet with one of the researchers each
month to ensure the device is working properly. You may be asked to periodically record your
home blood pressure before and during your use of the breathing relaxation device.
A physician’s assistant of registered nurse will conduct my blood pressure readings during the
course of treatment.
All information collected will be reviewed only by the experimenter and persons overseeing the
project. No information will be released to others unless you specifically request in writing that
this should be done.
You may discontinue my participation in this study at any time without penalty. If you do so and
want a referral for further or additional treatment, the researchers will provide you with a list of
professionals to consider.
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?
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To the best of our knowledge, the things you will be doing have no more risk of harm than you
would experience in everyday life.
This project is designed to help improve my blood pressure. If effective, there is a chance your
blood pressure may lower too much or too quickly, resulting in you taking too much medication.
This is one of the reasons your blood pressure will be monitored closely throughout the project
so adjustments can be made by your treating physician if needed.
You realize as well that your blood pressure may actually increase, although this is very unlikely.
You will be carefully monitored for this; should this occur, a referral made back to my physician
should this occur.
At the start of the study, you will be provided with information that alerts me to when my blood
pressure may be increasing or decreasing too much and what to do when this occurs.
You may find some questions we ask you (or some procedures we ask you to do) to be upsetting
or stressful. If so, we can tell you about some people who may be able to help you with these
feelings.
In addition to the risks listed above, you may experience a previously unknown risk or side
effect. If this occurs, you will have been given the phone number of the Lead Investigator, and
you should immediately call her. She will likely refer you to a local hospital or a medical facility.
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY?
There is no guarantee that you will receive any benefit from taking part in this study. However,
some people have experienced reductions in blood pressure when they have been given the
special education and/ or used the RESPeRATE, the device that you could be asked to use. You
may also be able to reduce some of your medications. If you are assigned to the waiting list
condition and reductions in blood pressure are seen over the course of the study in either of the
other two conditions, you can request that one of these 2 treatments be offered to you. Finally,
your willingness to take part may, in the future, help society as a whole better understand
hypertension and its treatment.
DO YOU HAVE TO TAKE PART IN THE STUDY?
If you decide to take part in the study, it should be because you really want to volunteer. You
will not lose any benefits or rights you would normally have if you choose not to volunteer. You
may stop at any time during the study and still keep the benefits and rights you had before
volunteering. If you decide not to take part in this study, your decision will have no effect on the
quality of care, services, etc., you currently receive.
IF YOU DO NOT WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER
CHOICES?
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If you do not want to take part in the study, there are other choices such as treatments at local
community health centers, hospitals, or emergency rooms. We will do our best to help you find
other such options.
WHAT WILL IT COST YOU TO PARTICIPATE?
There are no costs associated with taking part in the study. Any parking costs encountered by
coming to the University of Memphis will be covered by the research project.
WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY?
You could receive anywhere from $40-$70 in gift cards for taking part in this study, depending
on the condition to which you are assigned. Should you wish to withdraw your participation in
the study at any time, you will no longer be eligible for the remaining gift card amounts.
Depending on the condition you are assigned, you may also receive free use of the home training
device.
WHO WILL SEE THE INFORMATION THAT YOU GIVE?
We will make every effort to keep private all research records that identify you to the extent
allowed by law.
Your information will be combined with information from other people taking part in the study.
When we write about the study to share it with other researchers, we will write about the
combined information we have gathered. You will not be personally identified in these written
materials. We may publish the results of this study; however, we will keep your name and other
identifying information private.
Safeguarding Data:
All identifiable information provided by participants will be stored electronically separately on a
secure database and each participant will be assigned a non-identifiable subject code. Only
members of the trained research team will be allowed to enter data into the database. The two
databases will be stored on University of Memphis servers behind a firewall. The PI and her
faculty mentor will have access to the identifiable dataset. Upon project completion, this
information will be destroyed (unless carry-on funding is secured).
Additionally, a three-person Data Safety and Monitoring Board (DSMB) will be assembled to
ensure the safety of the participants. The DSMB will include the faculty mentor of this project,
the local medical doctor from the health clinic where recruitment will take place, and a publichealth focused biostatistician. The above-mentioned individuals will have access to the patient’s
medical information.
We will make every effort to prevent anyone who is not on the research team from knowing that
you gave us information, or what that information is. All medically-related paper records will be
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stored in the local medical clinic files, which are HIPPA compliant, industry regulated privacy
standards. All psychological outcome measures will be stored in a locked file cabinet in the
faculty mentor’s laboratory at the University of Memphis. Only the lead PI, the supervising
faculty mentor, and relevant research team members will have access to that key. These records
will be destroyed within 2 years of the date of completion of this project. The information within
these measures will be transferred to a password-protected electronic database immediately after
they are taken to the University of Memphis. Only the PI, her faculty advisor, and research team
members will have access to this database.
We will keep private all research records that identify you to the extent allowed by law.
However, there are some circumstances in which we may have to show your information to other
people. For example, the law may require us to show your information to a court if subpoenaed.
Also, we may be required to show information that identifies you to people who need to be sure
we have done the research correctly; these would be people from such organizations as the
University of Memphis.
CAN YOUR TAKING PART IN THE STUDY END EARLY?
If you decide to take part in the study you still have the right to decide at any time that you no
longer want to continue. You will not be treated differently if you decide to stop taking part in
the study.
The individuals conducting the study may need to withdraw you from the study. This may occur
if you are not able to follow the directions they give you, if they find that your being in the study
is more risk than benefit to you. There will be no consequences of withdrawing early from the
study.
WHAT HAPPENS IF YOU GET HURT OR SICK DURING THE STUDY?
If you believe you are hurt or if you get sick because of something that is due to the study, you
should call Ms. Paige Frankfurt, MS, Frank Andrasik, PhD, or Shawn Hayden, MD at 678-2146,
721-1200 or 911 immediately.
Frank Andrasik, PhD or Shawn Hayden, MD will determine what type of treatment, if any, that
is best for you at that time.
It is important for you to understand that the University of Memphis does not have funds set
aside to pay for the cost of any care or treatment that might be necessary because you get hurt or
sick while taking part in this study. Also, the University of Memphis will not pay for any wages
you may lose if you are harmed by this study.
Medical costs that result from research related harm cannot be included as regular medical costs.
Therefore, the medical costs related to your care and treatment because of research related harm
will be your responsibility.
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A co-payment/deductible from you may be required by your insurer or Medicare/Medicaid even
if your insurer or Medicare/Medicaid has agreed to pay the costs. The amount of this copayment/deductible may be substantial.
You do not give up your legal rights by signing this form.
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR
COMPLAINTS?
Before you decide whether to accept this invitation to take part in the study, please ask any
questions that might come to mind now. Later, if you have questions, suggestions, concerns, or
complaints about the study, you can contact the Lead Investigator, Paige Frankfurt at 901-6782146 or by email at pmgdvitz@memphis.edu. If you have any questions about your rights as a
volunteer in this research, contact the Institutional Review Board staff at the University of
Memphis at 901-678-2705. We will give you a signed copy of this consent form to take with
you.
WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT MIGHT
AFFECT YOUR DECISION TO PARTICIPATE?
If the researcher learns of new information in regards to this study, and it might change your
willingness to stay in this study, the information will be provided to you. You may be asked to
sign a new informed consent form if the information is provided to you after you have joined the
study.
WHAT ELSE DO YOU NEED TO KNOW?
The Center for Behavioral Medicine at The University of Memphis is providing material for this
study. If you have questions about subjects' rights, contact Beverly Jacobik, Administrator for
the Institutional Review Board for the Protection of Human Subjects, at irb@memphis.edu or by
phone at 901-678-2705.
Statement of Consent: I certify that I have read and fully understand the Statement of Procedure
and agree to participate in the research study described above. My permission is given
voluntarily without coercion or undue influence. I understand that I may discontinue my
participation at any time without penalty or loss of any benefits that I may be entitled. I will be
provided a copy of this consent form. Any questions I have are written below and have been
discussed with the experimenter
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
_____________________________________________
Signature of person agreeing to take part in the study
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______________________________________________
Printed name of person agreeing to take part in the study

____________
Date

______________________________________________
Name of [authorized] person obtaining informed consent

____________
Date
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APPENDIX B
DEMOGRAPHICS
Name:___________________________________________________________________
Age:_____________________________________________________________________
Zip Code:_________________________________________________________________
Date of Birth:_____________________________ Gender: M/F____________________
Please circle the answer that best described you:
1. What is your race?
Caucasian
Hispanic or Latino
Black or African American
Native American or American Indian
Asian / Pacific Islander
Other
2. What is the highest level of schooling that you have completed?
No schooling completed
Nursery school to 8th grade
Some high school, no diploma
High school graduate, diploma or the equivalent (for example: GED)
Some college credit, no degree
Trade/technical/vocational training
Associate degree
Bachelor’s degree
Master’s degree
Professional degree
Doctorate degree
3. What is your marital status?
Single, never married
Married or domestic partnership
Widowed
Divorced
Separated
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4. What is your current household income in U.S. dollars?
Under $10,000
$10,000 - $19,999
$20,000 - $29,999
$30,000 - $39,999
$40,000 - $49,999
$50,000 - $74,999
$75,000 - $99,999
$100,000 - $150,000
Over $150,000
Would rather not say
5. Do you currently have medical insurance?
Thank you and please continue on to the next page. When you have completed this packet, please
return it to the researcher, physician’s assistant, or the front desk staff.
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APPENDIX C
ID#
Literacy Items
Female Teachers - Document Literacy
Question:
What is the percentage of women in the teaching profession in Greece?
Answer:

Female Teachers - Document Literacy
Question:
List all the countries where the percentage of women teachers is between 60% and 75%.
Answer:
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APPENDIX D
Medications
“Now we’re going to ask you some questions about your HYPERTENSION medicines.”
1. Are you currently taking pills or other medicines to treat your HYPERTENSION?
Yes (Go to 2)
No (please continue to the next page)
It is important for us to understand what people with HYPERTENSION are really doing with
their pills or medicines. Please tell us what you are actually doing. We want to know what is
really happening, not what you think we want to hear.
2.

What are the names of the hypertension medications that you are taking (Please include
mg)

3.

How many times during the day has your doctor told you to take doses of medicine (pills
or other medicines) to treat your HYPERTENSION?
Once a day
Twice a day
Three times a day
Four or more times a day
What is the total number of pills your doctor has told you to take each day? (please type
in the total number of pills below)
|_____|_____| pills each day

4.
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